The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
Rs. 40 cr buyback, 200% dividend announced
New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
The submission is backed by positive results from the Phase 3 AFFIRM study
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
Subscribe To Our Newsletter & Stay Updated
